What is Ovagen? The Hepatic Bioregulatory Peptide
Summary
Ovagen is a research ultrashort peptide (tripeptide EDL: Glu-Asp-Leu) associated with hepatic/gastrointestinal bioregulation. Ultrashort peptides can enter cells and affect gene expression.
Substance Properties
What is Ovagen?
Ovagen is a synthetic ultrashort peptide — tripeptide Glu-Asp-Leu (EDL) — a member of the 'peptide bioregulator' family originally researched by Khavinson and colleagues. These peptides are studied for organ-directed gene expression effects, with Ovagen positioned for hepatic and gastrointestinal (GI) research.
Mechanism of action
Ultrashort peptides can enter cells, interact with DNA/histones, and regulate transcription related to tissue recovery and aging biology. The EDL motif itself has been structurally documented to bind enzyme active sites, demonstrating precise, sequence-specific bioactivity.
Hepatoprotective properties
In animal models, Ovagen exhibited hepatoprotective properties — improving liver function markers and potentially restoring normal transcription patterns in aged liver tissue. Data remains preclinical.
Related Guides
Frequently Asked Questions (FAQ)
Can Ovagen help with fatty liver disease?
There are no clinical data supporting this use. Ovagen is exclusively a research compound.
References & Studies
- Khavinson VK et al. Ultrashort peptides and hepatoprotection. Adv Gerontol. 2013;26(1):20-25.
Disclaimer
This article is exclusively educational for researchers. It does not constitute medical advice.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer